Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocyte Subsets | 3 | 2022 | 1837 | 0.700 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 2986 | 0.600 |
Why?
|
| Interleukin-2 | 1 | 2020 | 1887 | 0.440 |
Why?
|
| Coenzyme A | 1 | 2021 | 39 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 119 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 1038 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 4438 | 0.170 |
Why?
|
| Melanoma, Experimental | 2 | 2020 | 559 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 310 | 0.160 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 2542 | 0.150 |
Why?
|
| Neoplasms | 2 | 2022 | 21596 | 0.140 |
Why?
|
| Interleukins | 1 | 2020 | 791 | 0.130 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 3564 | 0.130 |
Why?
|
| Immunotherapy | 2 | 2022 | 4414 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2022 | 3199 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1820 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2022 | 2896 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 2915 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1255 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 9185 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1860 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3199 | 0.090 |
Why?
|
| Monocytes | 1 | 2019 | 2593 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 1423 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 21821 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2019 | 5019 | 0.070 |
Why?
|
| Animals | 7 | 2022 | 168561 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4823 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2019 | 7873 | 0.050 |
Why?
|
| Mice | 3 | 2022 | 81045 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5662 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 5519 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11472 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 792 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2020 | 209 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13655 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 471 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 678 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 23387 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 644 | 0.040 |
Why?
|
| Aged | 3 | 2022 | 162944 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 375 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 11001 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14554 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 986 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 1114 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 354 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2019 | 1284 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 540 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3471 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6313 | 0.030 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 490 | 0.020 |
Why?
|
| Endocytosis | 1 | 2016 | 983 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 2524 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 712 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 4322 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3133 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6891 | 0.020 |
Why?
|
| Humans | 7 | 2022 | 742088 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2016 | 3139 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2017 | 2614 | 0.020 |
Why?
|
| Ligands | 1 | 2016 | 3293 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9735 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 2500 | 0.020 |
Why?
|
| Cell Movement | 1 | 2019 | 5212 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4200 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10248 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12773 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2723 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8621 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15056 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2021 | 11470 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 13814 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12344 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 16665 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 10163 | 0.010 |
Why?
|
| Research Design | 1 | 2017 | 5979 | 0.010 |
Why?
|
| Female | 4 | 2020 | 379592 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2016 | 13029 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 19862 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40054 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29010 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 29717 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57683 | 0.010 |
Why?
|
| Middle Aged | 2 | 2020 | 213127 | 0.010 |
Why?
|
| Male | 2 | 2020 | 349538 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 213712 | 0.000 |
Why?
|
Concepts
(88)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_